Skip to main content
Menu

Posts tagged with "Drug Industry History"

  • Cancer

    Diminishing Returns

    As we slowly attack the major causes of disease, and necessarily pick the low-lying fruit in doing so, it can get harder and harder to see the effects of the latest advances. Nowhere, I’d say, is that more true than for cardiovascular disease, which is now arguably the most well-served therapeutic area of them all. Read More
  • Drug Assays

    Privileged Scaffolds? How About Unprivileged Ones?

    The discussion of “privileged scaffolds” in drugs here the other day got me to thinking. A colleague of mine mentioned that there may well be structures that don’t hit nearly as often as you’d think. The example that came to his mind was homopiperazine, and he might have a point; I’ve never had much luck… Read More
  • Drug Assays

    Privileged Scaffolds

    Here’s a new article on the concept of “privileged scaffolds”, the longstanding idea that there seem to be more biologically active compounds built around some structures than others. This doesn’t look like it tells me anything I didn’t know, but it’s a useful compendium of such structures if you’re looking… Read More
  • Business and Markets

    Where Would You Start a Company?

    We’ve been talking a lot around here about small companies versus large ones, the merits of different therapeutic areas, and so on. So here’s a question: if you were starting a small drug company today, where would you concentrate its efforts? Oncology? Ten years ago, you could make that case, I think. But now everyone’s… Read More
  • Business and Markets

    More On Pharma’s Ugly Finances

    Friday’s post has brought in a lot of comments, and they’re still piling up. I wanted to address a few of the more frequent ones, though, out here on the front page. First off, the idea that a bunch of stock analysts could have a useful opinion on a pharma company’s return on investment doesn’t… Read More
  • Drug Assays

    Polluting the Literature with PAINs

    There’s an article out from a group in Australia on the long-standing problem of “frequent hitter” compounds. Everyone who’s had to work with high-throughput screening data has had to think about this issue, because it’s clear that some compounds are nothing but trouble. They show up again and again as hits in all sort… Read More
  • Business and Markets

    Sheer Economics: How We Got in This Fix

    I hate to do another post on this subject, after a good part of the week has been devoted to layoff news and the like, but this one is too much to ignore. A reader sent along this link, which quotes a Morgan Stanley appraisal of the pharma industry as an investment. Here’s what they’re… Read More
  • Cardiovascular Disease

    Remember Apo-A1 Milano? Pfizer Does.

    The folks over at the In Vivo Blog will soon be announcing their “Deal of the Year” in the biotech/pharma sector (you can scroll back over there to see the various nominees). But they could just as well run the competition in reverse, and award some retroactive Bad Deal statues based on what’s been happening… Read More
  • Business and Markets

    The Cost of New Drugs

    I’m continuing my look at Bernard Munos’ paper on the drug industry, which definitely repays further study (previous posts here, here, and here). Now for some talk about money – specifically, how much of it you’ll need to find a new drug. The Munos paper has some interesting figures on this question, and the most… Read More
  • Business and Markets

    Another Take on the Munos Paper

    Eric Milgram over at PharmaConduct has an excellent post up on the same paper I’ve been discussing this morning. As another guy who’s been around the block a few times in this industry, he’s struck by many of the same points I am (to the point of also linking to Wikepedia’s page on Poisson distributions!) Read More
...282930...